Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patie...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2023-11-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13020 |
| _version_ | 1797255098629357568 |
|---|---|
| author | M. V. Shestakova V. A. Dobronravov A. S. Ametov M. B. Antsiferov M. M. Batyushin I. N. Bobkova G. R. Galstyan T. Y. Demidova V. V. Klimontov A. M. Mkrtumyan N. A. Petunina E. I. Prokopenko N. V. Chebotareva M. S. Shamkhalova |
| author_facet | M. V. Shestakova V. A. Dobronravov A. S. Ametov M. B. Antsiferov M. M. Batyushin I. N. Bobkova G. R. Galstyan T. Y. Demidova V. V. Klimontov A. M. Mkrtumyan N. A. Petunina E. I. Prokopenko N. V. Chebotareva M. S. Shamkhalova |
| author_sort | M. V. Shestakova |
| collection | DOAJ |
| description | Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patients in Russia relating to problems of underdiagnostics of CKD and substantial residual cardiorenal risks in these patients in spite of therapy with registered renoprotective medications. Finerenone is the first selective non-steroidal mineralocorticoid receptor antagonist which targets different from other drugs pathways involved in the pathogenesis of CKD in T2D. It has a significant potential to reduce residual renal and CV risks, and therefore addresses the existing therapeutic unmet need. According to the results of recent clinical studies, the cardio- and renoprotective effects of finerenone were apparent throughout a wide range of CKD C1-C4 in T2D patients, regardless of the severity of kidney dysfunction, the level of HbA1c and other drug therapy. This document summarizes the main results regarding the efficacy and safety profiles of finerenone and determines its place in treatment of CKD in T2D patients. |
| first_indexed | 2024-03-08T15:19:37Z |
| format | Article |
| id | doaj.art-cd40d33465dc4112b3b1b1597d367b81 |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:00:27Z |
| publishDate | 2023-11-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-cd40d33465dc4112b3b1b1597d367b812024-03-20T11:48:05ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782023-11-0126549249910.14341/DM1302011043Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory boardM. V. Shestakova0V. A. Dobronravov1A. S. Ametov2M. B. Antsiferov3M. M. Batyushin4I. N. Bobkova5G. R. Galstyan6T. Y. Demidova7V. V. Klimontov8A. M. Mkrtumyan9N. A. Petunina10E. I. Prokopenko11N. V. Chebotareva12M. S. Shamkhalova13Endocrinology Research CentreResearch Institute of Nephrology, Pavlov First Saint-Petersburg State Medical UniversityRussian Medical Academy of Continuing Professional EducationEndocrinological Dispensary of the Department of HealthRostov State Medical UniversityFirst Moscow State Medical University named after I.M. Sechenov (Sechenov University)Endocrinology Research Centre; Moscow Regional Research and Clinical Institute (MONIKI)Pirogov Russian National Research Medical UniversityResearch Institute of Clinical and Experimental Lymphology — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of SciencesMoscow State University of Medicine and Dentistry named after A.I. EvdokimovaFirst Moscow State Medical University named after I.M. Sechenov (Sechenov University)Moscow Regional Research and Clinical Institute (MONIKI)First Moscow State Medical University named after I.M. Sechenov (Sechenov University)Endocrinology Research CentreChronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patients in Russia relating to problems of underdiagnostics of CKD and substantial residual cardiorenal risks in these patients in spite of therapy with registered renoprotective medications. Finerenone is the first selective non-steroidal mineralocorticoid receptor antagonist which targets different from other drugs pathways involved in the pathogenesis of CKD in T2D. It has a significant potential to reduce residual renal and CV risks, and therefore addresses the existing therapeutic unmet need. According to the results of recent clinical studies, the cardio- and renoprotective effects of finerenone were apparent throughout a wide range of CKD C1-C4 in T2D patients, regardless of the severity of kidney dysfunction, the level of HbA1c and other drug therapy. This document summarizes the main results regarding the efficacy and safety profiles of finerenone and determines its place in treatment of CKD in T2D patients.https://www.dia-endojournals.ru/jour/article/view/13020finerenonenon-steroidal mineralocorticoid receptor antagonistdiabetes mellituschronic kidney disease |
| spellingShingle | M. V. Shestakova V. A. Dobronravov A. S. Ametov M. B. Antsiferov M. M. Batyushin I. N. Bobkova G. R. Galstyan T. Y. Demidova V. V. Klimontov A. M. Mkrtumyan N. A. Petunina E. I. Prokopenko N. V. Chebotareva M. S. Shamkhalova Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board Сахарный диабет finerenone non-steroidal mineralocorticoid receptor antagonist diabetes mellitus chronic kidney disease |
| title | Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board |
| title_full | Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board |
| title_fullStr | Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board |
| title_full_unstemmed | Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board |
| title_short | Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board |
| title_sort | prospects of finerenone use in russian population of patients with chronic kidney disease and type 2 diabetes resolution of multidisciplinary advisory board |
| topic | finerenone non-steroidal mineralocorticoid receptor antagonist diabetes mellitus chronic kidney disease |
| url | https://www.dia-endojournals.ru/jour/article/view/13020 |
| work_keys_str_mv | AT mvshestakova prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT vadobronravov prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT asametov prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT mbantsiferov prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT mmbatyushin prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT inbobkova prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT grgalstyan prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT tydemidova prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT vvklimontov prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT ammkrtumyan prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT napetunina prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT eiprokopenko prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT nvchebotareva prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard AT msshamkhalova prospectsoffinerenoneuseinrussianpopulationofpatientswithchronickidneydiseaseandtype2diabetesresolutionofmultidisciplinaryadvisoryboard |